Neurological Biomarkers Market to hit USD 26.6 billion by 2034, says Global Market Insights Inc.

Market Overview - The neurological biomarkers market was valued at USD 9.5 billion in 2024 and is projected to grow at a CAGR of 10.9% from 2025 to 2034 [1] - The growth is driven by the rising prevalence of neurodegenerative disorders such as Alzheimer's and Parkinson's disease, primarily due to the aging population [1] Key Drivers - Increasing awareness among patients and healthcare providers about neurological disorders [1][13] - Advancements in genomics, proteomics, and imaging technologies enhancing early detection and diagnosis of neurological diseases [2] - Growing demand for personalized medicine, which leads to better patient outcomes [2] Market Segmentation By Product Type - Proteomic biomarkers led the market in 2024 with a value of USD 3.1 billion, driven by advancements in technologies like liquid chromatography–mass spectrometry (LC-MS/MS) and multiplex assays [4] - Other segments include genomic, metabolomic, imaging, and other biomarkers [4] By Disease Type - Alzheimer's disease held the largest market share of 45.5% in 2024, reflecting the urgent need for early diagnostic solutions [6] - Blood-based biomarkers are emerging as a less invasive and cost-effective alternative to traditional cerebrospinal fluid tests [6] By End Use - Hospitals and clinics dominated the market in 2024 and are projected to reach USD 11 billion by 2034 [7] - These facilities are increasingly adopting non-invasive biomarker diagnostics to improve patient outcomes through personalized care [7] Regional Insights - North America, particularly the U.S., held a significant market share in 2024, valued at USD 3.7 billion [8] - The region benefits from technological advancements, increased focus on precision medicine, and rising demand for personalized therapies [8] Industry Ecosystem - The industry ecosystem is supported by government funding, research collaborations, and private sector involvement [7] - Key growth drivers include the increasing prevalence of neurological disorders, advancements in biomarker research, and the adoption of personalized medicine [13] Future Trends - The focus on precision medicine is expected to boost demand for proteomic biomarkers in both clinical settings and drug development [5] - Regulatory landscape, Porter's analysis, and PESTEL analysis are also shaping the future of the market [15] Major Players - Key companies in the market include Abbott Laboratories, ACOBIOM, Alseres Pharmaceuticals, Banyan Biomarkers, Bio-Rad Laboratories, DiaGenic ASA, Johnson & Johnson Services, Merck KGaA, QIAGEN, Quanterix, Rules-Based Medicine, and Thermo Fisher Scientific [9]